Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Loreal USA | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This research is being done to find out the safety and efficacy of two acne creams, Effaclar and Benzaclin when used twice daily with a topical retinoid. Effaclar and Benzaclin are FDA approved for the treatment of acne.
There are many products on the market to treat facial acne. The medication that this study will be evaluating, Benzaclin and Retin-A have been approved by the FDA and is available by prescription, Effaclar is an over the counter product. This study will hopefully recognize a treatment combination that is effective in reducing acne vulgaris in adults 18-50.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| BenzaClin | Active Comparator | Evaluate and compare tolerance and efficacy of two anti-acne creams, Effaclar and Benzaclin over a twelve week period.Inclusion- males and females ages 18-50, mild to moderate acne vulgaris with > or equal to 15 inflammatory lesions, > or equal to 20 non-inflammatory lesions, avoid excessive sun exposure or tanning beds throughout the study, . Exclusion- Participants who have another skin condition that will interfere with lesion counting or assessments |
|
| effaclar | Active Comparator | Evaluate and compare tolerance and efficacy of two anti-acne creams, Effaclar and Benzaclin over a twelve week period.Inclusion- males and females ages 18-50, mild to moderate acne vulgaris with > or equal to 15 inflammatory lesions, > or equal to 20 non-inflammatory lesions, avoid excessive sun exposure or tanning beds throughout the study, . Exclusion- Participants who have another skin condition that will interfere with lesion counting or assessments |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| BenzaClin | Drug | Topical, 1% Clindamycin/5% Benzoyl Peroxide, BID, 12 weeks |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Treatment Tolerability Assessment: Erythema | Participants were assessed for Erythema on a 4-point ordinal scale where 0= none; 1= mild; 2= moderate; and 3= severe. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16. | 16 weeks |
| Treatment Tolerability Assessment: Edema | Participants were assessed for Edema on a 4-point ordinal scale where 0= none; 1= mild; 2= moderate; and 3= severe. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16. | 16 weeks |
| Treatment Tolerability Assessment: Dryness | Participants were assessed for Dryness on a 4-point ordinal scale where 0= none; 1= mild; 2= moderate; and 3= severe. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16. | 16 weeks |
| Treatment Tolerability Assessment: Peeling | Participants were assessed for Peeling on a 4-point ordinal scale where 0= none; 1= mild; 2= moderate; and 3= severe. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16. | 16 weeks |
| Facial Skin Assessment: Skin Tone (Clarity) | The facial skin was assessed for skin tone (clarity) on a 10-point visual analog scale with 0 indicating a favorable rating and 9 indicating an unfavorable rating. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16. | 16 weeks |
| Facial Skin Assessment: Skin Smoothness |
Not provided
Not provided
Inclusion Criteria:males and females ages 18-50, mild to moderate acne vulgaris with > or equal to 15 inflammatory lesions, > or equal to 20 non-inflammatory lesions, avoid excessive sun exposure or tanning beds throughout the study
Exclusion Criteria:Participants who have another skin condition that will interfere with lesion counting or assessments
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Christian Oresajo, PhD | Loreal USA | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Penn State Hershey Medical Center | Hershey | Pennsylvania | 17033 | United States |
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | BenzaClin | Evaluate and compare tolerance and efficacy of two anti-acne creams, Effaclar and Benzaclin over a twelve week period. BenzaClin: Topical, 1% Clindamycin/5% Benzoyl Peroxide, BID, 12 weeks |
| FG001 | Effaclar | Evaluate and compare tolerance and efficacy of two anti-acne creams, Effaclar and Benzaclin over a twelve week period. Effaclar: Topical, (Benzoyl peroxide 5.5%) Bid, 12 weeks |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | BenzaClin | Evaluate and compare tolerance and efficacy of two anti-acne creams, Effaclar and Benzaclin over a twelve week period. BenzaClin: Topical, 1% Clindamycin/5% Benzoyl Peroxide, BID, 12 weeks |
| BG001 | Effaclar |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Treatment Tolerability Assessment: Erythema | Participants were assessed for Erythema on a 4-point ordinal scale where 0= none; 1= mild; 2= moderate; and 3= severe. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16. | Male and female 18-50 years old, mild to moderate acne vulgaris with >15 inflammatory lesions (papules/pustules) and >20 non-inflammatory lesions (black heads/white heads) on the face. | Posted | Mean | Full Range | score on a scale | 16 weeks |
|
16 weeks
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Effaclar | Evaluate and compare tolerance and efficacy of two anti-acne creams, Effaclar and Benzaclin over a twelve week period. Effaclar: Topical, (Benzoyl peroxide 5.5%) Bid, 12 weeks |
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Diane Thiboutot | Penn State Hershey Medical Center | 717-531-1513 | dthiboutot@pennstatehealth.psu.edu |
Not provided
| ID | Term |
|---|---|
| D000152 | Acne Vulgaris |
| ID | Term |
|---|---|
| D017486 | Acneiform Eruptions |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D012625 | Sebaceous Gland Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C466951 | clindamycin phosphate benzoyl peroxide combination |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Effaclar |
| Drug |
Topical, Bid, 12 weeks |
|
The facial skin was assessed for skin smoothness on a 10-point visual analog scale with 0 indicating a favorable rating and 9 indicating an unfavorable rating. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16.
| 16 weeks |
| Facial Skin Assessment: Skin Brightness | The facial skin was assessed for skin brightness on a 10-point visual analog scale with 0 indicating a favorable rating and 9 indicating an unfavorable rating. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16. | 16 weeks |
| Facial Skin Assessment: Appearance of Pores | The facial skin was assessed for the appearance of pores on a 10-point visual analog scale,with 0 indicating a favorable rating and 9 indicating an unfavorable rating. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16. | 16 weeks |
| Facial Skin Assessment: Overall Appearance | The facial skin was assessed for overall appearance on a 10-point visual analog scale with 0 indicating a favorable rating and 9 indicating an unfavorable rating. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16. | 16 weeks |
| Facial Skin Assessment: Global Acne Assessment | The facial skin was assessed for global acne assessment on a 10-point visual analog scale with 0 indicating a favorable rating and 9 indicating an unfavorable rating. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16. | 16 weeks |
| Facial Lesion Counts: Open Comedones | Participants were assessed for facial open comedomes and the total number present was recorded. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16. | 16 weeks |
| Facial Lesion Counts: Closed Comedones | Participants were assessed for facial closed comedomes and the total number present was recorded. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16. | 16 weeks |
| Facial Lesion Counts: Papules | Participants were assessed for facial open comedomes and the total number present was recorded. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16. | 16 weeks |
| Facial Lesion Counts: Pustules | Participants were assessed for facial pustules and the total number present was recorded. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16. | 16 weeks |
| Facial Lesion Counts: Noninflammatory Lesions | Participants were assessed for facial noninflammatory lesions and the total number present was recorded. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16. | 16 weeks |
| Facial Lesion Counts: Inflammatory Lesions | Participants were assessed for facial inflammatory lesions and the total number present was recorded. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16. | 16 weeks |
| Facial Lesion Counts: Total Lesion | Participants were assessed for all facial lesions and the total number present was recorded. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16. | 16 weeks |
| Subjective Tolerability of Irritation Assessment (Participant Assessed): Stinging | Irritation stinging was subjectively reported by participants and captured on a 4 point ordinal scale (0= none; 1= mild; 2= moderate; 3= severe). Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16. | 16 weeks |
| Subjective Tolerability of Irritation Assessment (Participant Assessed): Tingling | Irritation tingling was subjectively reported by participants and captured on a 4 point ordinal scale (0= none; 1= mild; 2= moderate; 3= severe). Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16. | 16 weeks |
| Subjective Tolerability of Irritation Assessment (Participant Assessed): Itching | Irritation itching was subjectively reported by participants and captured on a 4 point ordinal scale (0= none; 1= mild; 2= moderate; 3= severe). Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16. | 16 weeks |
| Subjective Tolerability of Irritation Assessment (Participant Assessed): Burning | Irritation burning was subjectively reported by participants and captured on a 4 point ordinal scale (0= none; 1= mild; 2= moderate; 3= severe). Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16. | 16 weeks |
Evaluate and compare tolerance and efficacy of two anti-acne creams, Effaclar and Benzaclin over a twelve week period.
Effaclar: Topical, (Benzoyl peroxide 5.5%) Bid, 12 weeks
| BG002 | Total | Total of all reporting groups |
| Participants |
|
| Age, Continuous | Mean | Standard Deviation | years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
|
|
| Primary | Treatment Tolerability Assessment: Edema | Participants were assessed for Edema on a 4-point ordinal scale where 0= none; 1= mild; 2= moderate; and 3= severe. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16. | Male and female 18-50 years old, mild to moderate acne vulgaris with >15 inflammatory lesions (papules/pustules) and >20 non-inflammatory lesions (black heads/white heads) on the face. | Posted | Mean | Full Range | score on a scale | 16 weeks |
|
|
|
| Primary | Treatment Tolerability Assessment: Dryness | Participants were assessed for Dryness on a 4-point ordinal scale where 0= none; 1= mild; 2= moderate; and 3= severe. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16. | Male and female 18-50 years old, mild to moderate acne vulgaris with >15 inflammatory lesions (papules/pustules) and >20 non-inflammatory lesions (black heads/white heads) on the face. | Posted | Mean | Full Range | score on a scale | 16 weeks |
|
|
|
| Primary | Treatment Tolerability Assessment: Peeling | Participants were assessed for Peeling on a 4-point ordinal scale where 0= none; 1= mild; 2= moderate; and 3= severe. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16. | Male and female 18-50 years old, mild to moderate acne vulgaris with >15 inflammatory lesions (papules/pustules) and >20 non-inflammatory lesions (black heads/white heads) on the face. | Posted | Mean | Full Range | score on a scale | 16 weeks |
|
|
|
| Primary | Facial Skin Assessment: Skin Tone (Clarity) | The facial skin was assessed for skin tone (clarity) on a 10-point visual analog scale with 0 indicating a favorable rating and 9 indicating an unfavorable rating. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16. | Male and female 18-50 years old, mild to moderate acne vulgaris with >15 inflammatory lesions (papules/pustules) and >20 non-inflammatory lesions (black heads/white heads) on the face. | Posted | Mean | Full Range | score on a scale | 16 weeks |
|
|
|
| Primary | Facial Skin Assessment: Skin Smoothness | The facial skin was assessed for skin smoothness on a 10-point visual analog scale with 0 indicating a favorable rating and 9 indicating an unfavorable rating. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16. | Male and female 18-50 years old, mild to moderate acne vulgaris with >15 inflammatory lesions (papules/pustules) and >20 non-inflammatory lesions (black heads/white heads) on the face. | Posted | Mean | Full Range | score on a scale | 16 weeks |
|
|
|
| Primary | Facial Skin Assessment: Skin Brightness | The facial skin was assessed for skin brightness on a 10-point visual analog scale with 0 indicating a favorable rating and 9 indicating an unfavorable rating. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16. | Male and female 18-50 years old, mild to moderate acne vulgaris with >15 inflammatory lesions (papules/pustules) and >20 non-inflammatory lesions (black heads/white heads) on the face. | Posted | Mean | Full Range | score on a scale | 16 weeks |
|
|
|
| Primary | Facial Skin Assessment: Appearance of Pores | The facial skin was assessed for the appearance of pores on a 10-point visual analog scale,with 0 indicating a favorable rating and 9 indicating an unfavorable rating. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16. | Male and female 18-50 years old, mild to moderate acne vulgaris with >15 inflammatory lesions (papules/pustules) and >20 non-inflammatory lesions (black heads/white heads) on the face. | Posted | Mean | Full Range | score on a scale | 16 weeks |
|
|
|
| Primary | Facial Skin Assessment: Overall Appearance | The facial skin was assessed for overall appearance on a 10-point visual analog scale with 0 indicating a favorable rating and 9 indicating an unfavorable rating. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16. | Male and female 18-50 years old, mild to moderate acne vulgaris with >15 inflammatory lesions (papules/pustules) and >20 non-inflammatory lesions (black heads/white heads) on the face. | Posted | Mean | Full Range | score on a scale | 16 weeks |
|
|
|
| Primary | Facial Skin Assessment: Global Acne Assessment | The facial skin was assessed for global acne assessment on a 10-point visual analog scale with 0 indicating a favorable rating and 9 indicating an unfavorable rating. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16. | Male and female 18-50 years old, mild to moderate acne vulgaris with >15 inflammatory lesions (papules/pustules) and >20 non-inflammatory lesions (black heads/white heads) on the face. | Posted | Mean | Full Range | score on a scale | 16 weeks |
|
|
|
| Primary | Facial Lesion Counts: Open Comedones | Participants were assessed for facial open comedomes and the total number present was recorded. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16. | Male and female 18-50 years old, mild to moderate acne vulgaris with >15 inflammatory lesions (papules/pustules) and >20 non-inflammatory lesions (black heads/white heads) on the face. | Posted | Mean | Full Range | Open Comedone Count | 16 weeks |
|
|
|
| Primary | Facial Lesion Counts: Closed Comedones | Participants were assessed for facial closed comedomes and the total number present was recorded. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16. | Male and female 18-50 years old, mild to moderate acne vulgaris with >15 inflammatory lesions (papules/pustules) and >20 non-inflammatory lesions (black heads/white heads) on the face. | Posted | Mean | Full Range | Closed Comedone Count | 16 weeks |
|
|
|
| Primary | Facial Lesion Counts: Papules | Participants were assessed for facial open comedomes and the total number present was recorded. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16. | Male and female 18-50 years old, mild to moderate acne vulgaris with >15 inflammatory lesions (papules/pustules) and >20 non-inflammatory lesions (black heads/white heads) on the face. | Posted | Mean | Full Range | Papule Count | 16 weeks |
|
|
|
| Primary | Facial Lesion Counts: Pustules | Participants were assessed for facial pustules and the total number present was recorded. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16. | Male and female 18-50 years old, mild to moderate acne vulgaris with >15 inflammatory lesions (papules/pustules) and >20 non-inflammatory lesions (black heads/white heads) on the face. | Posted | Mean | Full Range | Pustules Count | 16 weeks |
|
|
|
| Primary | Facial Lesion Counts: Noninflammatory Lesions | Participants were assessed for facial noninflammatory lesions and the total number present was recorded. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16. | Male and female 18-50 years old, mild to moderate acne vulgaris with >15 inflammatory lesions (papules/pustules) and >20 non-inflammatory lesions (black heads/white heads) on the face. | Posted | Mean | Full Range | Noninflammatory Lesion Count | 16 weeks |
|
|
|
| Primary | Facial Lesion Counts: Inflammatory Lesions | Participants were assessed for facial inflammatory lesions and the total number present was recorded. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16. | Male and female 18-50 years old, mild to moderate acne vulgaris with >15 inflammatory lesions (papules/pustules) and >20 non-inflammatory lesions (black heads/white heads) on the face. | Posted | Mean | Full Range | Inflammatory Lesion Count | 16 weeks |
|
|
|
| Primary | Facial Lesion Counts: Total Lesion | Participants were assessed for all facial lesions and the total number present was recorded. Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16. | Male and female 18-50 years old, mild to moderate acne vulgaris with >15 inflammatory lesions (papules/pustules) and >20 non-inflammatory lesions (black heads/white heads) on the face. | Posted | Mean | Full Range | Total Lesion Count | 16 weeks |
|
|
|
| Primary | Subjective Tolerability of Irritation Assessment (Participant Assessed): Stinging | Irritation stinging was subjectively reported by participants and captured on a 4 point ordinal scale (0= none; 1= mild; 2= moderate; 3= severe). Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16. | Male and female 18-50 years old, mild to moderate acne vulgaris with >15 inflammatory lesions (papules/pustules) and >20 non-inflammatory lesions (black heads/white heads) on the face. | Posted | Mean | Full Range | score on a scale | 16 weeks |
|
|
|
| Primary | Subjective Tolerability of Irritation Assessment (Participant Assessed): Tingling | Irritation tingling was subjectively reported by participants and captured on a 4 point ordinal scale (0= none; 1= mild; 2= moderate; 3= severe). Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16. | Male and female 18-50 years old, mild to moderate acne vulgaris with >15 inflammatory lesions (papules/pustules) and >20 non-inflammatory lesions (black heads/white heads) on the face. | Posted | Mean | Full Range | score on a scale | 16 weeks |
|
|
|
| Primary | Subjective Tolerability of Irritation Assessment (Participant Assessed): Itching | Irritation itching was subjectively reported by participants and captured on a 4 point ordinal scale (0= none; 1= mild; 2= moderate; 3= severe). Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16. | Male and female 18-50 years old, mild to moderate acne vulgaris with >15 inflammatory lesions (papules/pustules) and >20 non-inflammatory lesions (black heads/white heads) on the face. | Posted | Mean | Full Range | score on a scale | 16 weeks |
|
|
|
| Primary | Subjective Tolerability of Irritation Assessment (Participant Assessed): Burning | Irritation burning was subjectively reported by participants and captured on a 4 point ordinal scale (0= none; 1= mild; 2= moderate; 3= severe). Assessments were made at baseline and weeks, 2, 4, 8, and 12, with the regression phase assessment at week 16. | Male and female 18-50 years old, mild to moderate acne vulgaris with >15 inflammatory lesions (papules/pustules) and >20 non-inflammatory lesions (black heads/white heads) on the face. | Posted | Mean | Full Range | score on a scale | 16 weeks |
|
|
|
| 0 |
| 26 |
| 0 |
| 26 |
| 0 |
| 26 |
| EG001 | BenzaClin | Evaluate and compare tolerance and efficacy of two anti-acne creams, Effaclar and Benzaclin over a twelve week period. BenzaClin: Topical, 1% Clindamycin/5% Benzoyl Peroxide, BID, 12 weeks | 0 | 34 | 0 | 34 | 0 | 34 |
Not provided
Not provided
| Week 4 |
|
| Week 8 |
|
| Week 12 |
|
| Week 16 |
|
| Week 4 |
|
| Week 8 |
|
| Week 12 |
|
| Week 16 |
|
| Week 4 |
|
| Week 8 |
|
| Week 12 |
|
| Week 16 |
|
| Week 4 |
|
| Week 8 |
|
| Week 12 |
|
| Week 16 |
|
| Week 4 |
|
| Week 8 |
|
| Week 12 |
|
| Week 16 |
|
| Week 4 |
|
| Week 8 |
|
| Week 12 |
|
| Week 16 |
|
| Week 4 |
|
| Week 8 |
|
| Week 12 |
|
| Week 16 |
|
| Week 4 |
|
| Week 8 |
|
| Week 12 |
|
| Week 16 |
|
| Week 4 |
|
| Week 8 |
|
| Week 12 |
|
| Week 16 |
|
| Week 4 |
|
| Week 8 |
|
| Week 12 |
|
| Week 16 |
|
| Week 4 |
|
| Week 8 |
|
| Week 12 |
|
| Week 16 |
|
| Week 4 |
|
| Week 8 |
|
| Week 12 |
|
| Week 16 |
|
| Week 4 |
|
| Week 8 |
|
| Week 12 |
|
| Week 16 |
|
| Week 4 |
|
| Week 8 |
|
| Week 12 |
|
| Week 16 |
|
| Week 4 |
|
| Week 8 |
|
| Week 12 |
|
| Week 16 |
|
| Week 4 |
|
| Week 8 |
|
| Week 12 |
|
| Week 16 |
|
| Week 4 |
|
| Week 8 |
|
| Week 12 |
|
| Week 16 |
|
| Week 4 |
|
| Week 8 |
|
| Week 12 |
|
| Week 16 |
|
| Week 4 |
|
| Week 8 |
|
| Week 12 |
|
| Week 16 |
|
| Week 4 |
|
| Week 8 |
|
| Week 12 |
|
| Week 16 |
|